Abstracts tagged "Myositis"

Abstract Number: 1338 • 2018 ACR/ARHP Annual Meeting
Validation of the Diagnostic Accuracy of Myositis-Related Antibodies in a Large Patient-Cohort
Angelika Lackner¹, Viktoria Tiefenthaler², Jalia Mirzayeva², Winfried Graninger³ and Martin Stradner⁴, ¹Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ²Department of Rheumatology & Immunology, Medical University of Graz, Graz, Austria, ³Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁴Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Validation of the diagnostic accuracy of myositis-related antibodies in a large patient-cohortLackner, A; Tiefenthaler, V; Mirzayeva, J; Graninger, W; Stradner, MH Background/Purpose: Myositis-specific antibodies (MSA) and…
Abstract Number: 5L • 2017 ACR/ARHP Annual Meeting
Rapamycin Vs. Placebo for the Treatment of Inclusion Body Myositis: Improvement of the 6 Min Walking Distance, a Functional Scale, the FVC and Muscle Quantitative MRI
Olivier Benveniste¹, Jean-Yves Hogrel², Melanie Annoussamy², Damien Bachasson², Aude Rigolet³, Laurent Servais², Joe-Elie Salem⁴, Baptiste Hervier³, Oceane Landon Cardinal⁵, Kuberaka Mariampillai¹, Jean-Sebastien hulot⁴, Pierre Carlier² and Yves Allenbach⁶, ¹Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ²Institute of Myology, Paris, France, ³Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁴INSERM, CIC-1421, Paris, France, ⁵Internal Medicine, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrire University Hospital, Paris, France, ⁶Internal Medicine, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France

Background/Purpose: Inclusion body Myositis (IBM) is the most frequent myositis in patients over 50 years old. Conventional immunosuppressive drugs are today ineffective or even aggravate…
Abstract Number: 2137 • 2017 ACR/ARHP Annual Meeting
Clinical Factors Associated with Long-Term Damage and Calcinosis in an Adult-Age Referral Population of Juvenile Myositis Patients
Vladislav Tsaltskan¹, Annette Aldous², Sam Serafi¹, Heidi Sami¹, Gulnara Mamyrova¹, Frederick W Miller³, Sam Simmens², Rodolfo Curiel¹, Olcay Y. Jones⁴ and Lisa G Rider³, ¹Department of Rheumatology, George Washington University, Washington, DC, ²Department of Epidemiology and Biostatistics, George Washington University Milken Institute School of Public Health, Washington, DC, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁴Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are rare, autoimmune chronic muscle diseases of childhood with significant potential long-term morbidity. In this study we investigate associations…
Abstract Number: 2145 • 2017 ACR/ARHP Annual Meeting
Anti-CXCR3 Antibody Suppresses Inflammation in C Protein-Induced Myositis Model
Ji Yong Choi¹, Joo Youn Lee², Ji Soo Park³, Sehui Shon³, Kathleen Phillips⁴, Eun Young Lee¹, Eun Bong Lee¹ and Yeong Wook Song^3,5, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ²Department of Molecular medicine and biopharmaceutical science, Seoul National University, seoul, Korea, Republic of (South), ³Department of Molecular medicine and biopharmaceutical science, Seoul National University, Seoul, Korea, Republic of (South), ⁴Pfizer Inc. Cambridge, MA. USA, Cambridge, MA, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: CXCR3 is a chemokine receptor that plays an important role in T cell chemotaxis in human autoimmune diseases. CXCR3, which is activated by ligand…
Abstract Number: 2166 • 2017 ACR/ARHP Annual Meeting
Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Efficacy and Predictive Factors for Clinical Response
Simone Barsotti^1,2, Ilaria Cavazzana³, Rossella Neri⁴, Francesco Locatelli⁵, Mara Taraborelli^3,6, Elisa Cioffi⁷, Ilaria Chiapparoli⁵, Angela Tincani⁸, Franco Franceschini³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁴Rheumatology Unit, University of Pisa, PISA, Italy, ⁵Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foudation, Pavia, Italy, ⁶Internal Medicine; Ospedale Mellini, Chiari (Brescia), Italy, ⁷Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁸Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Despite the absence of specific guidelines or trials on intravenous immunoglobulins (IvIg) in patients with idiopathic inflammatory myopathies (IIM), the treatment is considered effective…
Abstract Number: 2309 • 2016 ACR/ARHP Annual Meeting
Focal Myositis: New Insights on Diagnosis and Pathology
Laure Gallay¹, Philippe Petiot², Arnaud Hot³, Francoise Thivolet-Bejui⁴ and Nathalie Streichenberger⁴, ¹Department of Internal Medicine, Edouard Heriot University Hospital, Hoscpices Civils de Lyon, Lyon cedex 03, France, ²Department of Neurology, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France, ³Department of Internal Medicine, Edouard Herriot University Hospital, Hospices Civils de Lyon, Lyon cedex 03, France, ⁴Department of Pathology, Neurology and Neurosurgery Pierre Wertheimer University Hospital, Hospices Civils de Lyon, Bron, France
Background/Purpose: Due to the rarity of the entity, the literature on focal myositis (FM) fails to address important questions on its nosology, associated disorders, clinical…
Abstract Number: 2315 • 2016 ACR/ARHP Annual Meeting
The Effectiveness of Social Media in Recruiting for Rare Rheumatic Diseases
Adam Schiffenbauer¹, Lisa G. Rider², Sara Faghihi-Kashani³, Komal Patel⁴ and Frederick W. Miller⁵, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, ⁴Social and Scientific Systems, Inc., Bethesda, MD, ⁵Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD
Background/Purpose: Clinical research is dependent on being able to recruit and enroll appropriate patients in sufficient numbers to make robust conclusions. For many diseases it…
Abstract Number: 2326 • 2016 ACR/ARHP Annual Meeting
Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease
Vincent Langlois¹, Kuberaka Mariampillai², Nicolas Champtiaux³, Marie-Laure Chabi⁴, Yurdagul Uzunhan⁵, Eric Hachulla⁶, Olivier Benveniste⁷ and Baptiste Hervier³, ¹Internal Medicine, University Hospital, Rouen, France, ²Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ³Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Radiology department, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁵Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁶Internal Medicine, Lille University Hospital, Lille, France, ⁷Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Interstitial lung disease (ILD) associated with inflammatory myopathy (IM) has a poor prognosis and requires specific treatments. Intravenous Cyclophosphamide (CYC) is one of the…
Abstract Number: 2456 • 2015 ACR/ARHP Annual Meeting
Anti SRP+Ve Myositis in Childhood. Presentation and Physiotherapy Treatment of This Rare Childhood Myositis
Susan Maillard and Clarissa Pilkington, Paediatric Rheumatology, Great Ormond Street Hospital NHS Foundation Trust for Children, London, United Kingdom
Background/Purpose: Previously it was understood that all Myositis in childhood was Juvenile Dermatomyositis. More recently Myositis specific antibodies have been discovered and these appear to…
Abstract Number: 288 • 2015 ACR/ARHP Annual Meeting
Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Niharika Sharma¹, Anisha Dua¹, Michael Putman², Rekha Vij³ and Mary Strek³, ¹Rheumatology, The University of Chicago, Chicago, IL, ²Internal Medicine, The University of Chicago, Chicago, IL, ³Pulmonology, The University of Chicago, Chicago, IL
Background/Purpose: Interstitial lung disease (ILD) frequently complicates Polymyositis (PM) and Dermatomyositis (DM) and accounts for significant morbidity and mortality in affected patients. Patients with Myositis…
Abstract Number: 302 • 2015 ACR/ARHP Annual Meeting
Resource Utilization in a US Sample of Patients with Sporadic Inclusion Body Myositis
Victoria Barghout¹, Carla DeMuro², Bob Goldberg³, Mark A Price², Linda Lowes⁴, Gorana capkun-Niggli⁵, Valerie Williams⁶ and Brian Tseng⁷, ¹VEB HealthCare LLC, Morristown, NJ, ²RTI Health Solutions, North Carolina, NC, ³The Myositis Association, Alexandria, VA, ⁴Nationwide Children’s Hospital, Columbus, OH, ⁵Novartis Pharmaceuticals Corporation, Basel, Switzerland, ⁶Psychometrics, RTI Health Solutions, North Carolina, NC, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Sporadic Inclusion Body Myositis (sIBM) is a progressive, idiopathic inflammatory myopathy characterized by dysphagia, weakness of proximal and distal muscles and atrophy. This cross-sectional…
Abstract Number: 2361 • 2015 ACR/ARHP Annual Meeting
Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: a Randomized, Treatment Delayed-Start Trial
Ingrid E. Lundberg¹, Anna Tjärnlund², Quan Tang³, Cecilia Wick², Maryam Dastmalchi⁴, Herman F Mann⁵, Jana Tomasová Studýnková⁵, Radka Chura⁶, Nicola J. Gullick⁷, Rosaria Salerno⁷, Eva Lindroos^3,8, Patrick Gordon⁶ and Jiri Vencovsky⁵, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Solna, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Department of Rheumatology, King`s College Hospital NHS Foundation Trust, London, United Kingdom, ⁷Rheumatology, Department of Rheumatology, King`s College Hospital NHS Foundation Trust, London, United Kingdom, ⁸Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden
Background/Purpose: The aim of the study was to assess the effects of abatacept, a T cell blocking agent, on disease activity and on muscle biopsy…
Abstract Number: 2375 • 2015 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Patients with Anti-PM-Scl Antibody
Hiromichi Tamaki¹, Ruchi Yadav², James Bena³ and Soumya Chatterjee⁴, ¹Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH, ²Diagnostic Radiology, Cleveland Clinic, Cleveland, OH, ³Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Patients with anti-PM-Scl antibody (PM-Scl) can present with several different phenotypes: polymyositis (PM), dermtomyositis (DM), systemic sclerosis (SSc), scleromyositis, or sclero-dermatomyositis. Interstitial Lung Disease…
Abstract Number: 2211 • 2014 ACR/ARHP Annual Meeting
Epidemiologic and Clinical Features of Patients with Adult and Juvenile Dermatomyositis, Polymyositis and Inclusion Body Myositis from Myovision, a National Myositis Patient Registry
Abdullah Faiq¹, Payam Noroozi Farhadi¹, Nastaran Bayat¹, Mikaela Chase¹, Anna Jansen¹, Karen Malley², Jesse Wilkerson³, Kathryn Rose⁴, Caroll Co⁴, Lukasz Itert⁵, Anne Johnson⁶, Richard Morris⁴, Christine Parks⁷, Edward H. Giannini⁸, Hermine I. Brunner⁸, Frederick W. Miller¹, Bob Goldberg⁹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Malley Research Programming, Inc, Bethesda, MD, ³Social and Scientific Systems, Inc., Research Triangle Park, NC, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Epidemiology Branch, NIEHS, NIH, Research Triangle Park, NC, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹The Myositis Association, Alexandria, VA
Background/Purpose: The myositis syndromes are rare systemic autoimmune diseases, little is known about their epidemiology. We describe the demographics and comorbidities of patients in a…
Abstract Number: 2216 • 2014 ACR/ARHP Annual Meeting
Muscle Type I Interferon Gene Expression May Predict Therapeutic Responses to Rituximab in Myositis Patients
Kanneboyina Nagaraju^1,2, Svetlana Ghimbovschi³, Sree Rayavarapu^2,4, Aditi Phadke⁴, Lisa G Rider⁵, Eric Hoffman^2,4 and Frederick W. Miller⁶, ¹Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, DC, ²Department of Integrative Systems Biology, The George Washington University, Washington, DC, ³Research Center for Genetic Medicine, Children's National Medical Center, Washington DC, WA, ⁴Research Center for Genetic Medicine, Children's National Medical Center, Washington, DC, ⁵Environmental Autoimmunity Group, Program of Clinical Research, National Institute of Environmental Health Sciences, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD, ⁶Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD
Background/Purpose To identify muscle gene expression patterns that predict rituximab responses and assess the effects of rituximab on muscle gene expression in polymyositis (PM) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].